Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

分组1 - Arbutus Biopharma reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing improvement from a loss of $0.11 per share a year ago, resulting in an earnings surprise of +150.00% [1] - The company posted revenues of $10.74 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 496.61%, compared to revenues of $1.73 million in the same quarter last year [2] - Over the last four quarters, Arbutus has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - Arbutus shares have increased by approximately 4.3% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $1.8 million, and for the current fiscal year, it is -$0.23 on revenues of $5.85 million [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 42% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]